2023 shaping up to be biggest year for biopharma M&A since pandemic (NYSE:PFE)

word m and a made with wood building blocks, stock image


word m and a made with wood building blocks, stock image

Maksim Labkouski

The IPO market may still be frigid, but 2023 is shaping up to be the biggest year for biopharma M&A since the pandemic, despite rising capital costs and increased scrutiny by antitrust regulators.

The sector has already seen $80B in dealsreport by Evaluate Pharma.

Leave a Reply

Your email address will not be published. Required fields are marked *